# the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women

> **NCT04619914** · NA · COMPLETED · sponsor: **Laylay Mohammed Khalleefah Alhibshi** · enrollment: 160 (actual)

## Conditions studied

- Endometrial Thickness
- Pregnancy Rate

## Interventions

- **DRUG:** Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt
- **DRUG:** letrozole (Femara; Novartis pharma AG, Basle, Switzerland)

## Key facts

- **NCT ID:** NCT04619914
- **Lead sponsor:** Laylay Mohammed Khalleefah Alhibshi
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-08-10
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04619914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04619914, "the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT04619914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*